Related Experiment Video
Updated: Mar 24, 2026
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
Published on: October 3, 2010
[Pediatric medulloblastoma: Retrospective series of 52 patients]
C Vigneron1, D Antoni1, A Coca2
1Département de radiothérapie, CLCC Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg, France.
Insights
This study on pediatric medulloblastoma found that conventional treatment (surgery followed by radiation) yields survival rates of 62% at 5 years. However, factors like positive cerebrospinal fluid impact prognosis, necessitating international treatment protocols.
Area of Science:
- Pediatric Oncology
- Radiation Oncology
- Neuro-oncology
Context:
- Medulloblastoma is a common malignant brain tumor in children.
- Treatment has evolved significantly over decades.
- Long-term outcomes require continuous evaluation.
Purpose:
- To retrospectively analyze treatment outcomes for pediatric medulloblastoma.
- To identify prognostic factors influencing survival.
- To evaluate the efficacy of surgery and radiotherapy.
Summary:
- 52 children with medulloblastoma received surgery and radiotherapy between 1974 and 2012.
- Mean follow-up was 106.6 months, with 13 relapses and 24 deaths.
- 5-year overall survival was 62%, and 5-year disease-free survival was 80%.
Impact:
- Confirms survival rates with conventional treatment for pediatric medulloblastoma.
- Highlights cerebrospinal fluid positivity as a negative prognostic factor.
- Underscores the need for international collaboration and standardized protocols due to tumor rarity and treatment complexities.
Purpose:
Retrospective analysis of the results of 52 children irradiated for a medulloblastoma.
Patients And Methods:
Between 1974 and 2012, 52 children with an average age of 6 years and a half (11 months-17 years and a half) were treated with surgery then with radiotherapy at the Comprehensive Cancer Centre of Strasbourg (France). For 44 children, the treatment consisted of a chemotherapy.
Results:
After a mean follow-up of 106.6 months (7-446 months), 13 relapses and 24 deaths were observed. Overall survival at 5 years and 10 years were 62% and 57%, respectively. Disease-free survival at 5 years and 10 years were 80% and 63%, respectively. Univariate analysis found the following adverse prognostic factors: the existence of a postoperative residue, the positivity of the cerebrospinal fluid, the metastatic status and medulloblastoma of high-risk. Positivity of the cerebrospinal fluid remains a negative factor in multivariate analysis.
Conclusion:
These results confirm the survival rate obtained by a conventional approach (surgery then irradiation). Insufficiency of results and rarity of medulloblastoma require the establishment of international protocols.
